First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

•CheckMate 227 evaluated first-line nivolumab + ipilimumab in patients with advanced NSCLC and tumor PD-L1 ≥1% or <1%.•We assessed outcomes of nivolumab + ipilimumab vs chemo in the Asian subpopulation, including Japanese patients.•Durable OS, PFS, and objective response benefits with nivolumab + ipilimumab vs chemo were observed at 3 years.•No new safety signals were identified among the Asian patients of CheckMate 227.•Results support the use of first-line nivolumab + ipilimumab for advanced NSCLC in Asian as well as Japanese patients.